regulatory t-cells + conventional t-cells

Regulatory T-cells + Conventional T-cells refers to a **cell therapy** or adoptive cell transfer product composed of two immunologically distinct T lymphocyte subsets: regulatory T cells (Tregs) and conventional T cells (often referred to as effector or conventional CD4+ and CD8+ T cells). Tregs are immunosuppressive and play essential roles in maintaining immune tolerance and preventing autoimmunity, while conventional T cells mediate immune responses against infected or malignant cells. Combination therapies or experimental interventions using both cell types seek to **modulate the immune system**—either promoting immune activity (e.g., against cancer, by inhibiting Treg suppression) or restoring tolerance (e.g., in autoimmune disease or transplantation by leveraging Treg activity). The precise use and balance of Tregs and conventional T-cells are experimentally tailored for disease context, with clinical research exploring adoptive transfer, depletion, or co-infusion to enhance anti-tumor immunity or suppress unwanted immune responses[1][3][4][7].